Clinical Report: The Past, Present and Future of Non-Target Screening

Overview

Non-target screening (NTS) has become a vital analytical method across various fields, enabling the identification of unknown compounds. The evolution of NTS emphasizes the importance of data management and interdisciplinary collaboration to enhance analytical capabilities.

Background

Non-target screening is crucial for advancing our understanding of complex samples in fields like environmental science and metabolomics. As the volume of molecular data increases, effective data handling and interpretation become essential. This approach is gaining traction in diverse areas, including food safety and pharmaceutical analysis, highlighting its growing relevance in modern analytical chemistry.

Data Highlights

No specific numerical data or trial data was provided in the source material.

Key Findings

• NTS allows for the detection of a broader range of contaminants beyond targeted monitoring lists.
• High-resolution mass spectrometry (HRMS) is increasingly accepted in toxicology for identifying unknown xenobiotics.
• Data management and machine learning are critical for the effective use of NTS.
• Collaboration across disciplines is essential for advancing NTS methodologies.
• Training and education in NTS are vital for laboratories to implement this analytical strategy effectively.

Clinical Implications

Clinicians and laboratories should consider integrating non-target screening into their analytical workflows to enhance the detection of unknown compounds. Continuous education and training in NTS methodologies will be essential for maximizing the potential of this analytical approach.

Conclusion

The future of non-target screening lies in its ability to adapt and integrate advanced data management techniques, making it a cornerstone of modern analytical practices. Continued collaboration and innovation will drive its evolution across various scientific disciplines.

References

1. The Analytical Scientist, 2026 -- New Frontiers in Non-Target Screening: Roundtable Symposium
2. The Analytical Scientist, 2026 -- Where Non-Target Screening Still Falls Short
3. ASCO Post, 2025 -- Noncancer-Related Mortality in RCTs With Targeted Screening
4. ANSI/ASB Standard 017, 2nd Ed., 2025 -- FACTSHEET FOR ANSI/ASB STANDARD 017, 2nd Ed., 2025
5. The New Gastroenterologist — Innovative Blood Test Shows Potential for Colorectal Cancer Screening in Average-Risk Adults
6. FACTSHEET FOR ANSI/ASB STANDARD 017, 2nd Ed., 2025
7. Fecal microbiota transplantation for hypertension: an exploratory, multicenter, randomized, blinded, placebo-controlled trial | Microbiome | Springer Nature Link